| Literature DB >> 26914862 |
Thazha P Prakash1, Jinghua Yu1, Michael T Migawa1, Garth A Kinberger1, W Brad Wan1, Michael E Østergaard1, Recaldo L Carty1, Guillermo Vasquez1, Audrey Low1, Alfred Chappell1, Karsten Schmidt1, Mariam Aghajan1, Jeff Crosby1, Heather M Murray1, Sheri L Booten1, Jill Hsiao1, Armand Soriano1, Todd Machemer1, Patrick Cauntay1, Sebastien A Burel1, Susan F Murray1, Hans Gaus1, Mark J Graham1, Eric E Swayze1, Punit P Seth1.
Abstract
The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported. Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs. The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice. Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs. GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins. This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a solution phase conjugation strategy. GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufacturing oligonucleotide drugs.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26914862 DOI: 10.1021/acs.jmedchem.5b01948
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446